UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 or 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2019
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrant’s name into English)
4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director Dealing
London, May 1, 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 29 April 2019, Darcy Nicolle, a person closely associated (PCA) with Wills Hughes-Wilson, Head of Patient Access, purchased 8000 ordinary shares at a price of GBP1.19 per share.
On 30 April 2019, Charles Sermon, General Counsel of Mereo BioPharma, purchased 6456 American Depositary Shares (ADSs) at a total price of USD6.00 per share and Richard Jones, Chief Financial Officer of Mereo BioPharma, purchased 1050 American Depositary Shares (ADSs) at a price of USD6.04 per share.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 | Details of the person discharging managerial responsibilities | |
a) | Name | Darcy Nicolle |
2 | Reason for the notification | |
a) | Position/status | Person closely associated (PCA) with Wills Hughes-Wilson, Head of Patient Access |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Mereo BioPharma Group plc |
b) | LEI | 213800U8JQHIJOS5AS09 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Ordinary Shares |
b) | Nature of the transaction | Purchase |
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
GBP1.19 |
8000 |
||||
d) | Aggregated information: volume, Price |
Aggregated volume: 8000
Aggregated price: GBP1.194 |
e) | Date of the transaction | 2019-04-29 |
f) | Place of the transaction | AIMX |
1 | Details of the person discharging managerial responsibilities | |
a) | Name | Charles Sermon |
2 | Reason for the notification | |
a) | Position/status | General Counsel |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Mereo BioPharma Group plc |
b) | LEI | 213800U8JQHIJOS5AS09 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs) |
b) | Nature of the transaction | PURCHASE |
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
USD6.04 |
6456 |
||||
d) | Aggregated information: volume, Price |
Aggregated volume: 6456
Aggregated price: USD6.00 |
e) | Date of the transaction | 2019-04-30 |
f) | Place of the transaction | XNMS |
1 | Details of the person discharging managerial responsibilities | |
a) | Name | Richard Jones |
2 | Reason for the notification | |
a) | Position/status | Chief Financial Officer |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Mereo BioPharma Group plc |
b) | LEI | 213800U8JQHIJOS5AS09 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | ADS |
b) | Nature of the transaction | Purchase |
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
USD5.94 |
1050 |
||||
d) | Aggregated information: volume, Price |
Aggregated volume: 1050
Aggregated price: USD5.94 |
e) | Date of the transaction | 2019-04-30 |
f) | Place of the transaction | XNMS |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: May 1, 2019
MEREO BIOPHARMA GROUP PLC | ||||
By: | /s/ Charles Sermon | |||
Name: | Charles Sermon | |||
Title: | General Counsel |